



PROMOTING GLOBAL COLLABORATION IN HBV CURE RESEARCH

Professor Peter Reville is a senior medical scientist at the Victorian Infectious Diseases Reference Laboratory (VIDRL), Royal Melbourne Hospital, located at the Peter Doherty Institute for Infection and Immunity, where he heads the Hepatitis Molecular Virology laboratory. His work focuses on the molecular virology of hepatitis B virus (HBV), particularly developing novel approaches to curing HBV infection and identifying mechanisms for HBV-associated liver cancer.

In addition to his research interests, Peter has most recently championed the establishment of the International Coalition to Eliminate Hepatitis B (ICE-HBV) that is facilitating coordinated approaches to HBV cure worldwide.

Peter is inaugural Chair of the ICE-HBV Governing Board.

Anna Suk-Fong Lok, MBBS (HK), MD (HK), DSc (Hons) (HK), FRCP (Edin), FAASLD, AGAF

駱淑芳

Alice Lohrman Andrews Research Professor in Hepatology

Professor of Internal Medicine

Director of Clinical Hepatology

Assistant Dean for Clinical Research

University of Michigan, Ann Arbor, Michigan, USA

President (2017), American Association for the Study of Liver Diseases

Dr. Lok graduated from the University of Hong Kong Medical School. She completed her medicine training at Queen Mary Hospital, Hong Kong and hepatology training in London under Dame Sheila Sherlock. She was a faculty at the University of Hong Kong until she moved to the United States in 1992. Dr. Lok joined the University of Michigan in 1995 as Director of the Hepatology Program. She became Associate Chair for Clinical Research in the Department of Internal Medicine in 2008 and Assistant Dean for Clinical Research in 2016.

Dr. Lok's research focuses on natural history and treatment of hepatitis B and C. She has published more than 500 papers on viral hepatitis and liver diseases including five iterations of the American Association for the Study of Liver Diseases (AASLD) guidelines on "Hepatitis B". She also participated in the development of the first World Health Organization guidelines on hepatitis B and C. Dr. Lok has made important contributions to the understanding of factors influencing the progression of hepatitis B and C, and the development of new treatments of these diseases. She was one of the top 1% most

cited researchers in the world for the period 2002-2012. Dr. Lok has mentored more than 50 fellows and junior faculty worldwide, many are now professors and heads of their departments.

Dr. Lok received many awards throughout her career including the Distinguished Scientist Award from the Hepatitis B Foundation and the Distinguished Women Scientist Award from the American Gastroenterological Association (AGA) in 2008, the Distinguished Service Award from the AASLD in 2011, the Distinguished Scientific Achievement Award from the American Liver Foundation in 2015, the William Beaumont Prize in Gastroenterology from the AGA in 2016, a Gold Medal Award from the Canadian Association for the Study of the Liver and an Hon DSc from the University of Hong Kong in 2017, and an International Recognition Award from the European Association for the Study of the Liver in 2018. Dr. Lok served as Associate Editor of HEPATOLOGY in 2002-6, co-Editor of Journal of Viral Hepatitis in 2007-9, Senior Associate Editor of GASTROENTEROLOGY in 2011-2012, and President of AASLD in 2017.

Mark Bulterys became Team Leader of the Global Hepatitis Programme at WHO-Geneva on Sept 1, 2016 (seconded by the U.S. Centers for Disease Control and Prevention (CDC) Division of Viral Hepatitis). In this WHO position, Dr. Bulterys provides scientific expertise and coordinates global technical activities related to viral hepatitis prevention and control. From 2013-2016, he was Associate Director for Science at the Naval Health Research Center in San Diego. From 2008-2013, he served as Director of the CDC Global AIDS Program in Beijing, China. From 2004–2008, he served as CDC Country Director in Lusaka, Zambia. He also served on detail as CDC Director in Haiti in 2011 during the cholera outbreak response; and CDC Ebola Response Lead in Guinea in Fall 2015. From 1998-2004, he was medical officer and team lead in the Epidemiology Branch, overseeing research on perinatal/pediatric HIV, including viral co-infections. He is currently in his 19th year with CDC. Prior to CDC, he was a fellow at the Viral Epidemiology Branch, U.S. National Cancer Institute, and a faculty member at the University of New Mexico School of Medicine. During this time, his primary research focus was on viral hepatitis. Marc also worked in Butare, Rwanda (1989-1993) for Johns Hopkins University. Dr. Bulterys is (co)author of 150+ peer-reviewed articles and 2 books. He received the Kellie Lartigue-Ndiaye Global Humanitarian Award and the Shepard Science Award at CDC. Dr. Bulterys received his M.D. training at the University of Leuven, Belgium, and a Ph.D. in epidemiology (minor in immunology and microbiology) as a Fulbright Scholar at the University of California at Los Angeles (UCLA).

Su Wang, MD MPH is the Medical Director for the Chinese Medical Program at Saint Barnabas Medical Center. She is board certified in Internal Medicine and Pediatrics, and primarily specializes in Adult Primary Care. She received her Medical Degree from the University of Miami and her Masters in Public Health from Johns Hopkins University. Dr. Wang completed her Internal Medicine and Pediatric residencies at Georgetown University Medical Center, and served as a fellow in the epidemic intelligence service for the Centers for Disease Control and Prevention (CDC). She is committed to Asian health and wellness, as well as the clinical identification and treatment of Hepatitis B (including infections in pregnancy).

She is President-Elect, World Hepatitis Alliance, Board Member, Hepatitis B Foundation, New York, USA.

Markus Cornberg, MD is Professor of Medicine for Infectious disease with emphasis on hepatitis and senior physician in the Department of Gastroenterology, Hepatology and Endocrinology at Hannover Medical School responsible for the infectious disease ward and the hepatitis outpatient clinic. Markus Cornberg is Clinical Director of the Helmholtz Centre for Infection Research (HZI) and Director of the Centre for Individualised Infection Medicine (CiiM). He is also the managing director of the German Competence Network for Viral Hepatitis (Hep-Net) and medical secretary of the German Liver Foundation. In 2007, 2011 and in 2017 he coordinated the German consensus process for the management of hepatitis B. In 2012 he was the German representative in the panel for the EASL Practice Guidelines for Hepatitis B. Since 2017 he is member of the scientific committee and the governing board of EASL. He has published more than 200 scientific articles on viral hepatitis and serves as a reviewer for several journals such as the Lancet, Gastroenterology, Hepatology, GUT, and the Journal of Hepatology.

Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on 'Antiviral therapy of viral hepatitis'. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and as head of the clinical viral hepatitis study section at ANRS. He served as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research. Furthermore, he has been the scientific coordinator of a European community-funded Network of Excellence on the management of antiviral drug resistance, and is currently head of the ANRS "HBV cure" program in France. He co-founded the International Coalition to Eliminate HBV (ICE-HBV: <http://www.ice-hbv.org>). Fabien Zoulim is a recognized expert in the field of viral hepatitis and antiviral therapy, and has published more than 400 articles (Web of Science H-index 73).